The effect of isradipine administration on existing fatty streaks in the cholesterol-fed rabbit: a morphometric study.
Previous studies have shown that the administration of certain calcium channel blocking drugs (at an appropriate time point) can reduce the severity of atherosclerotic lesion formation. This study was undertaken to determine if the administration of isradipine would reverse established lesions produced by feeding rabbits an atherogenic diet. Rabbits were fed cholesterol for three weeks and examined directly, or after being left for a four week washout period, with or without a daily oral supplement of isradipine. Fatty streaks were well established after three weeks of cholesterol feeding and were more extensive at the end of the washout period, as indicated by gross changes in the volume of the intima per unit length of aorta. When isradipine was administered during the washout period, the volume of the intima per unit length of aorta fell to levels below those produced by cholesterol feeding for three weeks alone. The major components of the lesions affected to accommodate these changes were the foam cells and myointimal cells; these were examined in detail using morphometry and lipid cytochemistry. The mean volume of intima/cm of aorta occupied by foam cells and myointimal cells both fell by more than 60% to levels lower than those found after three weeks of cholesterol feeding alone. The volume of the extracellular space of the intima occupied by cytochemically demonstrable unesterified and esterified cholesterol was reduced by isradipine administration as was that of foam cells, all to levels lower than those found after three weeks of cholesterol feeding alone. These data indicate that the administration of isradipine during a washout period, after cholesterol feeding, can promote the regression of fatty streak lesions.
Skepper
J N
JN
Department of Anatomy, University of Cambridge, UK.
Kappagoda
C T
CT
D000818:Animals; D001013:Aorta, Thoracic / Q000473:pathology; D001018:Aortic Diseases / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D001161:Arteriosclerosis / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D048429:Cell Size; D002784:Cholesterol / Q000008:administration & dosage / Q000633:toxicity*; D004036:Diet, Atherogenic; D004353:Drug Evaluation, Preclinical; D005260:Female; D005487:Foam Cells / Q000473:pathology; D017275:Isradipine / Q000627:therapeutic use*; D008055:Lipids / Q000032:analysis; D008854:Microscopy, Electron; D009131:Muscle, Smooth, Vascular / Q000473:pathology; D011817:Rabbits
D002121:Calcium Channel Blockers; D008055:Lipids; D002784:Cholesterol; D017275:Isradipine